CDK
Os inibidores das quinases dependentes de ciclinas (CDK) são compostos que bloqueiam a atividade das CDKs, um grupo de quinases de proteínas que regulam o ciclo celular, a transcrição e outros processos celulares. As CDKs são ativadas pela ligação às ciclinas, e sua atividade é crucial para a progressão das células através das diferentes fases do ciclo celular. Inibir as CDKs pode interromper a divisão celular, levando à parada do ciclo celular e à apoptose, especialmente em células cancerígenas onde as CDKs frequentemente estão desreguladas. Os inibidores de CDK são amplamente utilizados na pesquisa do câncer e têm potencial terapêutico no tratamento de vários tipos de câncer. Na CymitQuimica, oferecemos uma seleção abrangente de inibidores de CDK de alta qualidade para apoiar sua pesquisa em controle do ciclo celular, câncer e desenvolvimento terapêutico.
Foram encontrados 541 produtos de "CDK"
Ordenar por
Pureza (%)
0
100
|
0
|
50
|
90
|
95
|
100
Ribociclib succinate
CAS:Ribociclib succinate (LEE011 succinate) is a highly specific CDK4/6 inhibitor (IC50: 10 nM and 39 nM, respectively).Fórmula:C27H36N8O5Pureza:99.9%Cor e Forma:SolidPeso molecular:552.63Ref: TM-T15732
2mg34,00€5mg49,00€10mg70,00€25mg92,00€50mg109,00€100mg165,00€200mg258,00€500mg459,00€1mL*10mM (DMSO)60,00€Ca2+ channel agonist 1
CAS:Ca2+ channel agonist 1 activates N-type Ca2+ channels and inhibits Cdk2 (EC50: 14.23 μM/3.34 μM) for motor nerve issues.Fórmula:C19H26N6OPureza:97.71%Cor e Forma:SolidPeso molecular:354.45Ref: TM-T10659
1mg97,00€5mg188,00€10mg284,00€25mg452,00€50mg645,00€100mg867,00€200mg1.130,00€1mL*10mM (DMSO)217,00€Trilaciclib hydrochloride
CAS:Trilaciclib hydrochloride (G1T28 hydrochloride) is an inhibitor of CDK4/6 (IC50s: 1 nM and 4 nM for CDK4 and CDK6).Fórmula:C24H32Cl2N8OPureza:99.69% - 99.89%Cor e Forma:SolidPeso molecular:519.47CDK4/6-IN-2
CAS:CDK4/6-IN-2 是一种CDK4和CDK6抑制剂，IC50分别为 2.7 和 16 nM。Fórmula:C27H32F2N8Pureza:99.47%Cor e Forma:SolidPeso molecular:506.59NU6140
CAS:NU6140 is a selective inhibitor of CDK2-cyclin A (IC50, 0.41 μM).Fórmula:C23H30N6O2Pureza:98.33%Cor e Forma:SolidPeso molecular:422.52Ref: TM-T16359
2mg39,00€5mg60,00€10mg92,00€25mg177,00€50mg285,00€100mg414,00€200mg580,00€1mL*10mM (DMSO)67,00€Lerociclib dihydrochloride
CAS:Lerociclib dihydrochloride (G1T38 dihydrochloride) is a potent and selective inhibitor of CDK4/CDK6, with IC50s of 2 nM and 1 nM for CDK6/CyclinD3 and CDK4/Fórmula:C26H36Cl2N8OPureza:97.4%Cor e Forma:SolidPeso molecular:547.52Amantadine hydrochloride
CAS:Amantadine hydrochloride (CI-719) is an antiviral that is used in the prophylactic or symptomatic treatment of influenza A and Parkinson disease.Fórmula:C10H18ClNPureza:99.98%Cor e Forma:Solid CrystallinePeso molecular:187.71Nimbolide
CAS:Nimbolide, from neem, inhibits CDK4/6, NF-κB, Wnt, PI3K-Akt, MAPK, JAK-STAT pathways and induces apoptosis.Fórmula:C27H30O7Pureza:95.84% - 99.4%Cor e Forma:SolidPeso molecular:466.52Ref: TM-T16324
1mg71,00€5mg177,00€10mg305,00€25mg628,00€50mg867,00€100mg1.169,00€200mg1.520,00€1mL*10mM (DMSO)190,00€CDKI-73
CAS:CDKI-73: strong CDK9 blocker, Ki 4 nM, kills CLL cells selectively, aids cisplatin.Fórmula:C15H15FN6O2S2Pureza:98.11%Cor e Forma:SolidPeso molecular:394.45Ref: TM-T14919
1mg136,00€2mg178,00€5mg278,00€10mg399,00€25mg658,00€50mg888,00€100mg1.251,00€1mL*10mM (DMSO)290,00€CDK2-IN-4
CAS:CDK2-IN-4 is a potent and selective inhibitor of CDK2 with an IC50 of 44 nM for CDK2/cyclin A.Fórmula:C23H18N6O2SPureza:97.24% - 99.10%Cor e Forma:SolidPeso molecular:442.49Ref: TM-T14916
1mg82,00€5mg192,00€10mg304,00€25mg522,00€50mg713,00€100mg1.018,00€1mL*10mM (DMSO)212,00€hSMG-1 inhibitor 11j
CAS:hSMG-1 inhibitor 11j: pyrimidine, IC50=0.11 nM, >455x selective vs. mTOR/PI3Kα/γ/CDK1/CDK2; cancer research use.
Fórmula:C27H28ClN7O3SPureza:99.22% - 99.65%Cor e Forma:SolidPeso molecular:566.07MBQ-167
CAS:MBQ-167 is a dual inhibitor of Rac/Cdc42 (IC50s: 103 nM for Rac 1/2/3 and 78 nM for Cdc42 in MDA-MB-231 cells, respectively).Fórmula:C22H18N4Pureza:98.07% - 99.52%Cor e Forma:SolidPeso molecular:338.41Ref: TM-T16021
1mg37,00€2mg52,00€5mg79,00€10mg111,00€25mg208,00€50mg376,00€100mg567,00€1mL*10mM (DMSO)87,00€GSK-3 inhibitor 4
CAS:Orally active GSK-3 inhibitor 4 targets GSK-3α/β, CDK2/5 (IC50: 0.45-0.68 μM) and may aid in Alzheimer's research by lowering Tau protein.Fórmula:C22H15F2N5OPureza:99.82%Cor e Forma:SoildPeso molecular:403.38Ref: TM-T77341
1mg315,00€5mg873,00€10mg1.080,00€25mg1.431,00€50mg1.783,00€100mg2.250,00€500mg3.537,00€AZ1495
CAS:AZ1495: oral IRAK4 inhibitor (IC50: 5 nM), IRAK1 (23 nM), treats MYD88L265P DLBCL.Fórmula:C21H31N5O2Pureza:98.81%Cor e Forma:SolidPeso molecular:385.5Ref: TM-T14367
1mg93,00€5mg156,00€10mg245,00€25mg349,00€50mg494,00€100mg750,00€200mg1.009,00€1mL*10mM (DMSO)170,00€(R)-CR8
CAS:(R)-CR8 ((R)-Isomer) is a potent and selective CDK inhibitor.
Fórmula:C24H29N7OPureza:98.41%Cor e Forma:SolidPeso molecular:431.53Simurosertib
CAS:Simurosertib (TAK-931) is a selective and ATP-competitive cell division cycle 7 kinase inhibitor (IC50: <0.3 nM).Fórmula:C17H19N5OSPureza:99.93% - 99.93%Cor e Forma:SolidPeso molecular:341.43Ref: TM-T12642L
1mg62,00€5mg150,00€10mg203,00€25mg379,00€50mg533,00€100mg737,00€1mL*10mM (DMSO)157,00€XPW1
CAS:XPW1 is a CDK9 inhibitor with antitumor activity, inhibits DNA repair procedures, and can be used for the research of clear cell renal cell carcinoma.Fórmula:C36H39ClFN7O2Pureza:98.08%Cor e Forma:SoildPeso molecular:656.19BRD6989
CAS:BRD6989, a cortistatin A analog, inhibits CDK8/19, enhances IL-10, and binds CDK8 with a 200 nM IC50.Fórmula:C16H16N4Pureza:99.43%Cor e Forma:SolidPeso molecular:264.33Ref: TM-T14778
1mg34,00€5mg66,00€10mg92,00€25mg177,00€50mg268,00€100mg398,00€200mg575,00€1mL*10mM (DMSO)73,00€Cirtuvivint
CAS:Cirtuvivint (SM08502) is a potent and orally active CDC-like kinase (CLK) inhibitor that can be used to study arthritis.Fórmula:C24H25N7OPureza:99.95% - 99.96%Cor e Forma:SolidPeso molecular:427.5Samuraciclib hydrochloride
CAS:Samuraciclib HCl is an oral CDK7 inhibitor (IC50: 41 nM), 45-230x selective over CDK1/2/5/9, inhibiting breast cancer growth (GI50: 0.2-0.3 μM).Fórmula:C22H31ClN6OPureza:98.99% - 99.8%Cor e Forma:SolidPeso molecular:430.97Ref: TM-T10898
1mg108,00€2mg147,00€5mg222,00€10mg335,00€25mg595,00€50mg847,00€100mg1.153,00€1mL*10mM (DMSO)245,00€NVP-2
CAS:NVP-2 selectively inhibits CDK9 (IC50: 0.514 nM), prompts apoptosis, and affects other CDKs (IC50: 0.584-0.706 μM).Fórmula:C27H37ClN6O2Pureza:99.13%Cor e Forma:SolidPeso molecular:513.07Ref: TM-T16363
1mg52,00€2mg74,00€5mg113,00€10mg192,00€25mg416,00€50mg615,00€100mg875,00€1mL*10mM (DMSO)128,00€Garcinone C
CAS:Garcinone C, a xanthone from Garcinia oblongifolia, is anti-inflammatory, promotes healing, and may fight some cancers.Fórmula:C23H26O7Pureza:99.13% - 99.92%Cor e Forma:SolidPeso molecular:414.45Cyclin K degrader 1
Cyclin K degrader 1 is a Cyclin K degrader.Cyclin K degrader 1 is a degrader converted from AT-7519.Cyclin K degrader 1 has weak degrading activity against Cyclin K but does not result in a sustained decrease in degradation affinity.Cyclin K degrader 1 is a degrader converted from AT-7519.Fórmula:C23H17Cl2N5O2Pureza:99.76%Cor e Forma:SolidPeso molecular:466.32(±)-Enitociclib
CAS:(±)-Enitociclib ((±)-BAY-1251152) is a racemic mixture of BAY-1251152. BAY-1251152 is highly selective inhibitor of PTEF/CDK9.Fórmula:C19H18F2N4O2SPureza:99.29%Cor e Forma:SolidPeso molecular:404.43Ref: TM-T13467
1mg34,00€5mg84,00€10mg114,00€25mg205,00€50mg334,00€100mg537,00€200mg762,00€1mL*10mM (DMSO)93,00€JWZ-5-13
JWZ-5-13 is an effective CDK7 PROTAC degrader that significantly degrades CDK7 via the ubiquitin-proteasome system. JWZ-5-13 also exhibits antitumor activity.Fórmula:C54H66N10O6SPeso molecular:982.48875MeBIO
CAS:MeBIO is an agonist of aryl hydrocarbon receptor, with IC50 of 44 and 55 μM for GSK-3 and CDK1/CyclinB, respectively. MeBIO does not affect GSK-3β.Fórmula:C17H12BrN3O2Pureza:99.64%Cor e Forma:SolidPeso molecular:370.2Ref: TM-T21966
1mg39,00€5mg74,00€10mg117,00€25mg220,00€50mg354,00€100mg520,00€500mg1.130,00€1mL*10mM (DMSO)86,00€CPS2
CAS:CPS2: potent, selective PROTAC CDK2 degrader. IC50=24nM, targets acute myeloid leukemia research.Fórmula:C38H42N12O10S2Cor e Forma:SolidPeso molecular:890.94BSJ-5-63
CAS:BSJ-5-63 is an effective degrader of CDK12, CDK7, and CDK9. It reduces the protein expression of CDK12, CDK7, CDK9, RNAPII, and Cyclin K, and also decreases the mRNA expression of BRCA1 and BRCA2. BSJ-5-63 exhibits anticancer activity and holds potential for prostate cancer research.Fórmula:C52H74ClN9O6S2Cor e Forma:SolidPeso molecular:1020.78(1S,3R,5R)-PIM447 dihydrochloride
(1S,3R,5R)-PIM447 (dihydrochloride) an inhibitor of PIM(IC50 of 0.095 μM for Pim1, 0.522 μM for Pim2 and 0.369 μM for Pim3).Fórmula:C24H25Cl2F3N4OPureza:98%Cor e Forma:SolidPeso molecular:513.38FDA-Approved Kinase Inhibitor Library
A unique collection of 263 kinase inhibitors/regulators for specific targeting of kinases, ready for high-throughput screening and high-content screening.
Cor e Forma:LiquidPROTAC FLT3/CDKs degrader-1
PROTACFLT3/CDKs degrader-1 (Compound C3) is an agent that degrades cyclin-dependent kinase (CDK2 with a DC50 of 18.73 nM) and FMS-like tyrosine kinase 3 (FLT3). It induces differentiation in HL-60 cells, achieving a 72.77% differentiation rate at 6.25 nM, and inhibits proliferation of acute myeloid leukemia (AML) cells, with an IC50 ranging from 2.9 to 37 nM. PROTACFLT3/CDKs degrader-1 demonstrates potential for improving the treatment of AML.
Fórmula:C40H42N12O5Peso molecular:770.34011Olomoucine
CAS:Olomoucine hinders Cdk2, Cdc2, CDK5, ERK1, regulates the cell cycle, and fights melanoma; IC50s: 3-25 µM.
Fórmula:C15H18N6OPureza:99.77%Cor e Forma:White Crystalline PowderPeso molecular:298.34dCeMM3
CAS:dCeMM3 is a glue degrader that induces ubiquitination and degradation of cyclin K by promoting CDK12-cyclin K interaction with CRL4B ligase.
Fórmula:C14H11ClN4OSPureza:98.48% - 99.41%Cor e Forma:SolidPeso molecular:318.78LSN3106729 hydrochloride
CAS:LSN3106729 hydrochloride, an Abemaciclib metabolite, is a CDK-inhibiting antitumor PROTAC CDK4/6 degrader.Fórmula:C25H29ClF2N8OCor e Forma:SoildPeso molecular:531.00Maleimide-PEG8-Val-Ala-PAB-SNS032
Maleimide-Val-Ala-PAB-SNS032 is a conjugated compound used as an ADC toxin and linker. SNS032 acts as a CDK inhibitor, reducing cancer cell viability and arresting the cell cycle at the G1/S phase. Maleimide-Val-Ala-PAB functions as a cleavable ADC linker. Maleimide-Val-Ala-PAB-SNS032 is utilized in the synthesis of ADC molecules.Fórmula:C59H87N9O18S2Peso molecular:1273.56105CDK9 degrader-1
CDK9degrader-1 is a selective CDK9 degrader (DC50: 0.4073 µM). It recruits ATG101 to initiate the autophagy-lysosome pathway and forms autophagosomes by recruiting LC3, which then fuse with lysosomes to degrade CDK9 and its partner protein, Cyclin T1 (DC50: 1.215 µM). CDK9degrader-1 induces caspase 3-mediated apoptosis and exhibits antitumor activity in a mouse HCT116 xenograft model.Fórmula:C32H34Cl2N6O4Cor e Forma:SolidPeso molecular:637.56GW297361
CAS:GW297361 is a potent inhibitor of the cell cycle protein-dependent kinase Cdk1 and also inhibits the Pho85 signaling pathway.The IC50s of GW297361 on yeast Cdk1Fórmula:C16H12N4O3S2Pureza:98.30%Cor e Forma:SolidPeso molecular:372.42Anticancer agent 264
Anticanceragent 264 (Compound 5w) is an anticancer compound that exhibits significant antiproliferative activity in tumor cell lines, with an IC50 range of 7.5-33.67 μM. It notably induces cell cycle arrest at the G2/M phase in MDA-MB-231, MIA PaCa-2, and DU-145 cell lines. This compound reduces key cell cycle proteins CDK1, CDK2, and Cyclin B1 in a dose-dependent manner and has strong binding activity with differentiation inhibitors and DNA-binding proteins. Anticanceragent 264 is useful for research in the cancer disease domain.Fórmula:C23H18ClF5N6OCor e Forma:SolidPeso molecular:524.87IMPDH2-IN-4
IMPDH2-IN-4 (compound 2d) is a Mycophenolic acid analog and a selective IMPDH2 inhibitor with a Ki of 1.8 μM. It exhibits potent cytotoxic activity against osteosarcoma cancer cell lines. Additionally, IMPDH2-IN-4 demonstrates high affinity for VEGFR-2, CDK2, and IMPDH.Fórmula:C35H34O6SiCor e Forma:SolidPeso molecular:578.73AM5992
CAS:AM5992 (example 195) is a potent CDK4 and CDK6 inhibitor (CDK4, IC50= 0.013 μM). AM5992 can be used for the research of CDK4-mediated disorders.
Fórmula:C27H33FN8OPureza:98%Cor e Forma:SoildPeso molecular:504.6CDK2-IN-7
CAS:CDK2-IN-7 is a CDK2 inhibitor for treating cancer ( IC 50 < 50 nM).Fórmula:C24H30N6O4SCor e Forma:SolidPeso molecular:498.6[pThr3]-CDK5 Substrate
CAS:[pThr3]-CDK5 Substrate is an effective Phospho-Thr3CDK5 Substrate.[pThr3]-CDK5 Substrate is phosphorylated by CDK5 with a Km value of 6 µM[1].Fórmula:C53H100N15O15PPureza:98%Cor e Forma:SolidPeso molecular:1218.43PROTAC CDK9 degrader-5
CAS:PROTAC CDK9 degrader-5 selectively degrades CDK9 isoforms 42, 55 with DC50 of 0.10μM, 0.14μM via proteasome.Fórmula:C42H48Cl2N8O9Pureza:98%Cor e Forma:SolidPeso molecular:879.78NecroIr1
NecroIr1, an iridium(III) complex, induces necroptosis in Cisplatin-resistant lung cells, targeting mitochondria and disrupting MMP.Fórmula:C40H29ClIrN5OCor e Forma:SolidPeso molecular:823.36Roccellic Acid
CAS:Roccellic acid from R. montagnei lichen has antibacterial, anticancer properties; MIC 46.9 μg/ml; inhibits cancer cells by up to 87.9%.Fórmula:C17H32O4Cor e Forma:SolidPeso molecular:300.43JH-XI-10-02
CAS:JH-XI-10-02 selectively degrades CDK8 (IC50: 159 nM) through proteasome, sparing CDK8 mRNA and CDK19.
Fórmula:C53H69N5O9Pureza:98%Cor e Forma:SolidPeso molecular:920.1613-Methylthienyl-carbonyl-JNJ-7706621
CAS:Potent CDK inhibitor 3-Methylthienyl-carbonyl-JNJ-7706621, IC50: CDK1=6.4nM, CDK2=2nM, GSK-3=0.041μM; moderate on CDK4/VEGF-R2/FGF-R2.Fórmula:C14H14N6O3S2Cor e Forma:SolidPeso molecular:378.43CDK2/PIM1-IN-1
CDK2/PIM1-IN-1 is an inhibitor of the kinases CDK2 (IC50: 0.27 μM) and PIM1 (IC50: 0.67 μM). It can induce apoptosis (cell death) and reduce the expression of TNF-α, which promotes tumors. CDK2/PIM1-IN-1 exhibits antitumor activity.
Cor e Forma:Odour SolidBLINK15
BLINK15 is a blood-brain barrier-permeable Cdk5 inhibitor. It reduces CDK5 activity in CDK5/p35 (IC50= 29.34 nM) and CDK5/p25 (IC50= 12.08 nM) complexes. Additionally, BLINK15 exhibits antidiabetic and neuroprotective effects. It lowers blood glucose levels in type 2 diabetes (T2D) mice, enhances cognitive abilities, and diminishes neurodegenerative lesions.Cor e Forma:Odour SolidCDK7-IN-2 hydrochloride hydrate
CAS:CDK7-IN-2 HCl hydrate is a potent, specific CDK7 enzyme inhibitor with significant anti-cancer effects.Fórmula:C26H42ClN7O4Cor e Forma:SolidPeso molecular:552.12WAY-322243
CAS:WAY-322243 has antibacterial and anti-inflammatory activity and has an inhibitory effect on CLK-1, which can be used to study Alzheimer's disease.Fórmula:C18H18N2O2SPureza:99.88%Cor e Forma:SoildPeso molecular:326.41Abemaciclib metabolite M18
CAS:Abemaciclib M18 (LSN3106729), a potent CDK inhibitor with antitumor action, used in a PROTAC to degrade CDK4/6.Fórmula:C25H28F2N8OPureza:98%Cor e Forma:SolidPeso molecular:494.54CDK2/4-IN-1
CDK2/4-IN-1 (compound B-4a) serves as both a CDK2/4 inhibitor and a microtubule polymerization inhibitor, making it useful in cancer research.Cor e Forma:Odour Solid(E/Z)-THZ1 2HCl
CAS:THZ1 2HCl: selective CDK7 allosteric inhibitor, IC50 3.2 nM, hinders cancer cell growth.
Fórmula:C31H30Cl3N7O2Pureza:99.51%Cor e Forma:SolidPeso molecular:638.98PROTAC CDK9 degrader-7
CAS:PROTAC CDK9 degrader-7 is a proteolysis-targeting chimera (PROTAC) specifically designed to target and mediate the degradation of Cyclin-Dependent Kinase 9 (Fórmula:C43H50Cl2N8O9Cor e Forma:SoildPeso molecular:893.81BSJ-03-204
CAS:BSJ-03-204 is a selective Cdk4/6 degrader.Fórmula:C43H48N10O8Cor e Forma:SolidPeso molecular:832.9CDK9/EZH2-IN-1
CAS:CDK9/EZH2-IN-1 is a dual-target inhibitor of CDK9 and EZH2 with IC50 values of 83.9 nM and 108.6 nM, respectively. It induces apoptosis and causes DNA double-strand breaks (DSB). Additionally, CDK9/EZH2-IN-1 inhibits the proliferation of MKN45, MDA-MB-453, and SW620 cancer cells, with respective IC50 values of 136.3 nM, 171.3 nM, and 315.7 nM.Fórmula:C47H59N11O4S2Cor e Forma:SolidPeso molecular:906.17CDK7-IN-6
CAS:CDK7-IN-6, a potent CDK7 inhibitor (IC50 ≤100 nM), from WO2019197549 A1, is >200x selective over CDK1/2/5, promising for cancer research.Fórmula:C26H34ClN9OCor e Forma:SolidPeso molecular:524.07JH-XVI-178
CAS:JH-XVI-178: potent CDK8/19 inhibitor with good pharmacokinetics, low clearance, moderate oral bioavailability.Fórmula:C22H22ClN7OCor e Forma:SolidPeso molecular:435.92PP-C8
PP-C8: PROTAC CDK12-Cyclin K degrader with DC50s 416/412 nM; synergizes with PARP inhibitor against TNBC.Fórmula:C43H51FN12O7Cor e Forma:SolidPeso molecular:866.94Kinase Inhibitor Library
A unique collection of 2720 kinase inhibitors/regulators for high throughput screening and high content screening for drug discovery in kinase related diseases;Cor e Forma:Odour SolidRef: TM-L1600
1mgA consultar30μL*10mM (DMSO)A consultar50μL*10mM (DMSO)A consultar100μL*10mM (DMSO)A consultar250μL*10mM (DMSO)A consultarPROTAC CDK9 degrader 4
CAS:PROTAC CDK9 degrader 4 is a CDK9 degrader that targets transcriptional regulation and has potential anticancer activity.Fórmula:C43H56N10O5Cor e Forma:SolidPeso molecular:792.97CDK7/9-IN-1
CAS:CDK7/9-IN-1 inhibits CDK7/9 with IC50: 0.0656 μM (no pre-incubation), 0.00574 μM (3h pre-inc.), and CDK9: 2.14 μM (3h pre-inc.) for cancer research.Fórmula:C24H32F3N5O2Cor e Forma:SolidPeso molecular:479.548A-130A
CAS:A-130A is a polycyclic polyether compound belonging to the nigericin group of antibiotics generated by Streptomyces hygroscopicus strain.Fórmula:C47H78O13Pureza:98%Cor e Forma:SolidPeso molecular:851.11[Ala92]-p16 (84-103)
CAS:Peptide derived from the tumor suppressor protein p16; inhibits cyclin-dependent kinase-4 (cdk4)/cyclin D1 (IC50 ~ 1.5 μM) and binds to cdk6.Fórmula:C93H155N31O26Pureza:98%Cor e Forma:SolidPeso molecular:2123.44CDK12-IN-4
CAS:CDK12-IN-4 is a pyrazolotriazine that inhibits CDK12 (IC50: 0.641 μM) with high ATP (2 mM) and spares CDK2/Cyclin E and CDK9/Cyclin T1 (IC50: >20 μM).Fórmula:C20H20F2N8OCor e Forma:SolidPeso molecular:426.432Cdk2/Cyclin Inhibitory Peptide II
CAS:Cdk2/Cyclin Inhibitory Peptide II (Tat-LDL), a CDK2 inhibitor, demonstrates dose-dependent cytotoxic effects on U2OS osteosarcoma cells [1].Fórmula:C110H200N48O25Cor e Forma:SolidPeso molecular:2595.07CDK4/6-IN-11
CAS:CDK4/6-IN-11 is a potent PROTAC CDK4/6 degrader.Fórmula:C43H49N11O7Cor e Forma:SolidPeso molecular:831.92Men 10376
CAS:Men 10376 is a selective antagonist of tachykinin NK-2 receptor. It has a Ki of 4.4 μM for rat small intestine NK-2 receptor.Fórmula:C57H68N12O10Pureza:98%Cor e Forma:SolidPeso molecular:1081.22SNX7
CAS:SNX7 (WAY-323879) inhibits CDKI pathway; useful for studying aging and related diseases.Fórmula:C15H14N2OPureza:99.96%Cor e Forma:SolidPeso molecular:238.28CDK6/9-IN-1
CAS:CDK6/9-IN-1, an oral dual inhibitor of CDK6/9, has IC50s of 40.5nM (CDK6) and 39.5nM (CDK9).
Fórmula:C22H25ClN8OCor e Forma:SolidPeso molecular:452.95LL-K8-22
LL-K8-22: potent CDK8/cyclin C degrader; DC50 ~2.5μM; hinders STAT1 phosphorylation; curbs E2F/MYC cancer pathways; for TNBC study.Fórmula:C37H43N5OCor e Forma:SolidPeso molecular:573.77CDK-IN-12
CAS:CDK-IN-12 (Example 20), a CDK inhibitor, effectively inhibits CDK4/6, demonstrating IC50 values below 20 nM [1].Fórmula:C26H29FN6OSCor e Forma:SolidPeso molecular:492.61CDK7-IN-5
CAS:CDK7-IN-5, a CDK7 inhibitor with an IC 50 value of less than 100 nM, exhibits potent anticancer properties (WO2015154022A1, Compound 104).Fórmula:C34H45N9O2Cor e Forma:SolidPeso molecular:611.795PROTAC CDK9 degrader-2
CAS:PROTAC CDK9 degrader-2, potent, selective, IC50 17 μM in MCF-7, wogonin-derived, targets CRBN.Fórmula:C39H36N6O10Pureza:98%Cor e Forma:SolidPeso molecular:748.74CDK7-IN-1
CAS:CDK7-IN-1, analog of YKL-5-124, inhibits cdk7 with IC50 < 100 nM.Fórmula:C28H35N7O3Cor e Forma:SolidPeso molecular:517.634HTH-01-091 TFA
HTH-01-091 TFA: Potent, selective MELK inhibitor (IC50=10.5 nM); also targets PIM1/2/3, RIPK2, DYRK3, smMLCK, CLK2; used in breast cancer research.Fórmula:C28H29Cl2F3N4O4Cor e Forma:SolidPeso molecular:613.46EGFR/CDK2-IN-4
EGFR/CDK2-IN-4 (compound 4c) is a dual inhibitor targeting EGFR and CDK-2, demonstrating IC50 values of 89.6 nM for EGFR and 165.4 nM for CDK-2.Fórmula:C24H16N6OS2Pureza:98%Cor e Forma:SolidPeso molecular:468.55BSJ-04-132
Selective Cdk4 degrader. Degrades Cdk4 in Molt-4 cells, with no effect on Cdk6 levels. Displays cereblon-dependent degradation.Cor e Forma:LiquidCDK4/6-IN-5
CAS:CDK4/6-IN-5 inhibits CDK4/6; Ki: 0.2 nM (CDK4/D1) & 4.4 nM (CDK6/D3). (WO2019207463A1, A93)Fórmula:C22H28ClFN6O4SCor e Forma:SolidPeso molecular:527.01Multi-target kinase inhibitor 2
Compound 5K (Multi-target kinase inhibitor 2) is a multi-targeted kinase inhibitor demonstrating activity against EGFR, Her2, VEGFR2, and CDK2 with IC50 valuesPureza:98%Cor e Forma:Odour SolidCDK12-IN-6
CAS:CDK12-IN-6, a pyrazolotriazine, strongly inhibits CDK12 (IC50 1.19 μM at 2 mM ATP), but not CDK2/Cyclin E or CDK9/Cyclin T1 (both IC50 >20 μM).Fórmula:C20H21F2N9Cor e Forma:SolidPeso molecular:425.448TMX-2138
CAS:TMX-2138 is a CDKs PROTAC degrader, with IC50 values of 8.7 nM for CDK1/cyclinB, 10.9 nM for CDK2/cyclinA, 7.0 nM for CDK5/p25, and 25.7 nM for CDK9/cyclinT1. It enhances the ubiquitination and degradation of CDKs and is utilized for ovarian cancer research.Fórmula:C40H43BrFN9O11SCor e Forma:SolidPeso molecular:956.791CDK9 inhibitor HH1
CAS:CDK9 inhibitor HH1 (8019-9719) is an inhibitor of the human CDK2-cyclin A2 complex with an IC50 value of 2 μM.
Fórmula:C13H15N3OSPureza:99.92%Cor e Forma:SolidPeso molecular:261.34NecroIr2
NecroIr2, an iridium(III) compound, induces necroptosis in Cisplatin-resistant A549R lung cancer cells and disrupts mitochondria.Fórmula:C46H30ClIrN6O2Cor e Forma:SolidPeso molecular:926.44XY028-133
CAS:XY028-133 is a PROTAC-based CDK4/6 degrader for the study of tumors.
Fórmula:C53H67N11O7SPureza:97.11%Cor e Forma:SolidPeso molecular:1002.23CDK9-IN-25
CDK9-IN-25 (compound 4a), an imidazopyrazine derivative, functions as a CDK9 inhibitor with an IC50 of 0.24 μM.
Fórmula:C15H16FN5Pureza:98%Cor e Forma:SolidPeso molecular:285.32EGFR/CDK2-IN-2
EGFR/CDK2-IN-2 (compound 6a) serves as a dual inhibitor targeting both EGFR and CDK-2, exhibiting IC50 values of 19.6 nM and 87.9 nM, respectively.Fórmula:C49H32N12O2S2Pureza:98%Cor e Forma:SolidPeso molecular:884.99Cdk2/Cyclin Inhibitory Peptide I
CDK2, a Ser/Thr kinase, is akin to yeast cdc28 and human Cdk1, crucial for cell division.Fórmula:C111H196N48O23Pureza:98%Cor e Forma:SolidPeso molecular:2571.05CDK7-IN-7
CAS:CDK7-IN-7: Selective CDK7 inhibitor, IC50 < 50 nM (Patent CN112661745A).
Fórmula:C20H20BrF3N6O2Cor e Forma:SolidPeso molecular:513.319CDK7-IN-21
CAS:CDK7-IN-21 (compound A22) is a potent CDK7 inhibitor [1] .Fórmula:C33H36FN9O2Cor e Forma:SolidPeso molecular:609.7PROTAC CDK9 degrader-11
CAS:PROTAC CDK9 degrader-11 (Compound C3) is an orally active PROTAC CDK9 degrader with a DC50 of 1.09 nM. This compound exhibits cytotoxicity in small cell lung cancer (SCLC) cells, with IC50 values in the nanomolar range. It induces cell cycle arrest at the G0/G1 phase and inhibits cell invasion in DMS114 and DMS53 cells. In addition, PROTAC CDK9 degrader-11 shows antitumor activity in an NCI-H446 xenograft mouse model. (Pink: ligand for target protein CDK9 ligand 3; Black: linker; Blue: ligand for E3 ligase Cereblon E3 ligase Ligand 56)Fórmula:C39H48Cl2N10O5Cor e Forma:SolidPeso molecular:807.768IV-361
CAS:IV-361, an orally active and selective CDK7 inhibitor with a Ki value of less than or equal to 50 nM, demonstrates potent anti-cancer activity (US20190256531A1Fórmula:C23H32FN5O2SiCor e Forma:SolidPeso molecular:457.625PROTAC CDK9 degrader-8
PROTAC CDK9 Degrader-8 (Compound 21) is a potent degrader of CDK9 with an IC50 of 0.01 μM, utilized in cancer research [1].Fórmula:C44H52Cl2N10O7Pureza:98%Cor e Forma:SolidPeso molecular:903.85CDK12/13-IN-2
CDK12/13-IN-2 (Compound 24) is a covalent inhibitor of CDK12 and CDK13, exhibiting IC50 values of 15.5 nM and 12.2 nM, respectively. It effectively inhibits the proliferation of breast cancer cells and can be utilized in the research of triple-negative breast cancer.Fórmula:C24H22FN7O2Cor e Forma:SolidPeso molecular:459.48EGFR/CDK2-IN-3
EGFR/CDK2-IN-3 (compound 4b) serves as a dual inhibitor targeting both EGFR and CDK-2, exhibiting IC50 values of 71.7 nM and 113.7 nM, respectively.Fórmula:C30H20N6OSPureza:98%Cor e Forma:SolidPeso molecular:512.58CDK9 ligand 3
CAS:CDK9ligand 3 is a ligand for CDK9 and can be utilized in the synthesis of PROTAC degraders, specifically PROTAC CDK9degrader-11.
Fórmula:C18H18BrCl2N5O3Cor e Forma:SolidPeso molecular:503.177CDK2-IN-43
CDK2-IN-43 (Compound 3a) is a CDK2-cyclin E2 inhibitor with an IC50 value of 6.0 nM. It is applicable to cancer research.Fórmula:C19H27N7OCor e Forma:SolidPeso molecular:369.464CDK5-IN-1
CAS:CDK5-IN-1: Potent CDK5 inhibitor (<10 nM) used in kidney disease research.Fórmula:C24H25FN6O3SCor e Forma:SolidPeso molecular:496.56
![[pThr3]-CDK5 Substrate](/_next/image/?url=https%3A%2Fstatic.cymitquimica.com%2Fproducts%2FTM%2Fthumb-webp%2FTP1602.webp&w=3840&q=75)
![[Ala92]-p16 (84-103)](/_next/image/?url=https%3A%2Fstatic.cymitquimica.com%2Fproducts%2FTM%2Fthumb-webp%2FTP2133.webp&w=3840&q=75)
